Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 18, keine Gesamtzahl für „section“
Suchtreffer
Begriffe & Kennungen
Byooviz · 4.5 · For the adjunctive use of laser photocoagulation and ranibizumab in DME and BRVO, see sections 4.2 and 5.1.
Eintrag öffnenBysumlog · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenBysumlog · 4.5 · The physician should be consulted when using other medications in addition to Bysumlog (see section 4.4).
Eintrag öffnenCabazitaxel Accord · 4.5 · In vitro studies have shown that cabazitaxel is mainly metabolised through CYP3A (80% to 90%) (see section 5.2
Eintrag öffnenCabazitaxel Accord · 4.8 · Haematuria In the pooled analysis, haematuria all grades frequency was 18.8% at 25 mg/m2 (see section 5.1). Co
Eintrag öffnenCabazitaxel Accord · 4.8 · Paediatric population See section 4.2
Eintrag öffnenCablivi · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenCabometyx · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenCabometyx · 4.8 · 16 Haemorrhage (see section 4.4) In the RCC study (METEOR), the incidence of severe haemorrhagic events (Grade
Eintrag öffnenCabometyx · 4.8 · Diarrhoea (see section 4.4) In the RCC study (METEOR), diarrhoea was reported in 74% of cabozantinib-treated R
Eintrag öffnenCabometyx · 4.8 · Fistulas (see section 4.4) In the RCC study (METEOR), fistulas were reported in 1.2% (4/331) of cabozantinib-t
Eintrag öffnenCabometyx · 4.8 · Gastrointestinal (GI) perforation (see section 4.4) In the RCC study (METEOR), GI perforations were reported i
Eintrag öffnenCabometyx · 4.8 · Hepatic encephalopathy (see section 4.4)
Eintrag öffnenCabometyx · 4.8 · Paediatric population (see section 5.1)
Eintrag öffnenCabometyx · 4.8 · Posterior reversible encephalopathy syndrome (PRES) (see section 4.4) No case of PRES was reported in the METE
Eintrag öffnenCaelyx pegylated liposomal · 4.3 · Hypersensitivity to the active substance, peanut or soya, or to any of the excipients listed in section 6.1.
Eintrag öffnenCalquence · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenCalquence · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenCamzyos · 4.3 · ▪ Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. ▪ During pregnan
Eintrag öffnenCancidas (previously Caspofungin MSD) · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnen